Akamis Bio is a biotechnology company focused on developing innovative gene-based immuno-oncology treatments for solid tumors. Utilizing its proprietary intravenously administered T-SIGn virus platform, Akamis Bio aims to create effective cancer therapies that deliver therapeutic agents directly to the tumor while minimizing systemic exposure. The company is committed to advancing its internal pipeline of early and clinical-stage candidates, as well as forging strategic partnerships with leaders in the immuno-oncology field to enhance the reach and impact of its products. Akamis Bio's goal is to be a leading player in cancer gene therapy, providing valuable medicines to patients facing challenging cancer diagnoses.
Hybrid BioSystems develops gene therapy treatments for ovarian and prostate cancer. It exploits the interface between polymer chemistry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.